DOCSLIB.ORG

Infliximab-Refractory Checkpoint Colitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Infliximab-Refractory Checkpoint Colitis Infliximab-Refractory Checkpoint Colitis Michael Dougan, MD, PhD Director of the Immunotherapy Mucosal Toxicies Program Assistant Professor of Medicine Division of Gastroenterology Massachuses General Hospital 22 June 2019 Disclosures • Novars (research funding), Genentech (consulng), Tillots (consulng), Moderna (consulng) • I will be talking about non FDA approved indicaons for infliximab (and other an-TNF medicaons), and vedolizumab Treatment Refractory Enterocolitis • DB is a 55 yoW w/ metastac breast cancer on ipilimumab/nivolumab combinaon therapy as part of a clinical trial • Four weeks aer compleng cycle one, she developed severe, watery diarrhea associated with cramping abdominal pain • Typical presentaon for checkpoint inhibitor enterocolis The gut is the most immunologically complex barrier in the body Careful immune regulaon is essenal • Dietary proteins • Commensal bacteria • Pathogenic microorganisms • Toxins Abreu et al. Nat. Rev. Imm. 2010 Disruption of immune homeostasis leads to a wide- spectrum of common GI toxicities (Entero)colis Hepa,s Dougan M. Froners in Immunology. 2017. The spectrum is dependent on the pathway targeted Dougan M. Froners in Immunology. 2017. Enterocolitis • (Entero)colis is the most common GI toxicity from current checkpoint blocking anbodies (CTLA-4, PD-1, PD-L1) • Range of severity (many paents have indolent disease) • Likely responsible for most treatment related diarrhea • Oen isolated to the colon, but can involve the Dougan M. Froners in Immunology. 2017. GI tract from stomach to rectum CTLA-4 and PD-1/PD-L1 have different regulatory roles in the gut Ipilimumab colis PD1-blockade colis • More frequent and more severe • more microscopic inflammaon • Rapid onset • Indolent course • Dose-dependent • Dose-independent (?) • Rapidly resolves • Slow resoluon DB underwent endoscopic examination Severe checkpoint inhibitor colis was confirmed TNFα is likely a key driver of checkpoint colitis • Most paents with checkpoint colis respond to steroids • 30-40% of severe cases are steroid refractory • Infliximab (an-TNFα) is highly effecve in ipilimumab and an-PD1 mediated colis • Suggests a crical funconal role for this cytokine in disease pathogenesis • We have a low threshold for using it (41% of our checkpoint colis paents go on infliximab) • Similar rates for ipilimumab and an-PD-1 colis, but ipilimumab colis seems to respond faster • Vedolizumab also appears to be effecve in some paents (Abu-Sbeih et al. JITC. 2018) • Trafficking of new T cells into the gut probably plays a role in maintaining inflammaon Can we predict who is going to need infliximab? • All current data are retrospecve • Two published case series found an associaon with colonic ulceraon (Wang et al. IBD. 2018, Geukes et al. ESMO Open. 2018) • In our MGH cohort of 49 paents with detailed endoscopic and oncologic clinical data: • Mayo Endoscopic Score is higher in paents who need infliximab (1.14 vs 2.26 out of 3, p = 0.001) • No associaon with CTCAE grade (2.05 vs 1.95) • MES 3 (ulcers) is associated with an increased need for infliximab (p < 0.009) • No associaon with rectal bleeding • Paents with enteris tend to get infliximab more oen (p = 0.08) • No associaon with pathway inhibited (PD-1 vs CTLA-4) Corticosteroids were ineffective • Within 72 hours of diagnosis, she was started on infliximab (5 mg/kg) • She received dose 2 one week later for incomplete response • She received a total of 4 doses (week 0, 1, 2, 6) with an inially good response, but she was unable to taper the steroids below 20 mg daily What if patients don’t respond to infliximab? • Reconfirm the diagnosis: • Infecons (C Diff, CMV, fungal) happen in a significant fracon of paents • We have seen treatment emergent Celiac Disease (TTG-IgA+, gluten-free diet responsive) • Pancreac insufficiency can occur (Eshet et al. CIR. 2018) Repeat endoscopy Persistent checkpoint enterocolis And if checkpoint enterocolitis is reconfirmed? • This queson has not been adequately addressed in the literature • Best data is for vedolizumab (Abu-Sbeih et al. JITC. 2018) • Vedolizumab has some risks: • Oen must be given while an-TNF is sll circulang • Will block trafficking of immune cells to tumors located in the gut (GI tumors, but also metastac disease – 5% of melanomas) What other options do we have? • Surgery: appropriate for colonic disease, and otherwise healthy paents) • Ustekinumab (an-IL-12/23 p40): approved for Crohn’s with some acvity in UC • Other cytokine inhibitors (an-IL-1β, IL-6) • JAK inhibitors: approved for UC • CTLA-4-Ig: effecve at treang CTLA-4 haploinsufficiency, which is associated with enteris • Both JAK inhibitors and CTLA-4Ig likely inhibit the antumor response What about FMT? Wang, Y et al. Nature Medicine. 2019 Vedolizumab was started • She responded aer the inial dose and has been connued for a full load (weeks 0, 2, and 6) • Infliximab was stopped • Steroids have been tapered with recrudescence • We have also used ustekinumab, abatacept, and FMT successfully in other select situaons Acknowledgements MGH Cancer Center MGH GI Dana-Farber Cancer Institute Memorial Sloan-Kettering Kerry Reynolds Molly Thomas Stephanie Dougan David Faleck Alexandra-Chloe Villani Md Aladdin Bhuyian Kai Wucherpfennig Ryan Sullivan Andy Chan Adrienne Louma Novartis Justine Cohen Ramnik Xavier Lestat Ali Glenn Dranoff Leyre Zubiri Osama Rahma Meghan Mooridian NIH/CTEP Elizabeth Buchbinder Donald Lawrence Elad Sharon Stephen Hodi Keith Flaherty Patrick Ott Riley Fadden MD Anderson Cancer Center Jonathan Schoenfeld Krista Rubin Hussein Tawbi Genevieve Boland Yinghong (Mimi) Wang MIT/Koch Tatyana Sharova Michael Birnbaum Maclean Sellers .
Load more

Recommended publications
  • Positioning Biologics in the Management of Moderate to Severe Crohn's Disease
    REVIEW CURRENT OPINION Positioning biologics in the management of moderate to severe Crohn’s disease Jana G. Hashash and Fadi H. Mourad Purpose of review Since there is a lack of head-to-head randomized controlled trials, little direction is provided from guidelines on the positioning of biologics for the treatment of Crohn’s disease (CD). This review utilizes comparative effectiveness and safety results from real-world data and network meta-analyses to inform clinical practice for positioning of biological therapies in the treatment of moderate-to-severe CD. Recent findings We summarize the results of studies pertaining to the identification of predictors for response to biologics in CD. Recently published studies about the management of moderate-to-severe CD are discussed and a positioning algorithm is proposed for the therapeutic approach of these patients. Summary Different classes of biologics are comparable with regards to safety and almost similar in effectiveness in the management of CD. There are certain clinical scenarios in which one biologic is more effective than another. For instance, patients with a more aggressive disease phenotype such as fistulizing disease would benefit from infliximab over other biologics, whereas in older patients at a higher risk for infectious complications, it may be more appropriate to use ustekinumab or vedolizumab over the anti-tumor necrosis factor (TNF) agents. More data pertaining to identifying predictors of response to the different available therapies and head-to-head comparison trials are needed to personalize our therapeutic approach of CD patients. Keywords biologics, Crohn’s disease, moderate-to-severe, positioning INTRODUCTION The medical management of patients with CD To guide the choice of treatment in patients with has changed over recent years.
    [Show full text]
  • Cutaneous Adverse Effects of Biologic Medications
    REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions
    [Show full text]
  • B.C. Pharmacare Drug Information Sheet for Vedolizumab (Entyvio)
    The drug below is being considered for possible coverage under the B.C. PharmaCare program. PharmaCare is a government-funded drug plan that helps British Columbians with the cost of eligible prescription drugs and specific medical supplies. For more information on PharmaCare, visit Ministry of Health - PharmaCare. PharmaCare reviews each drug for treating a specific illness or medical condition (known as an “indication”). If a decision is made to cover the drug, it will be only for that illness or condition. In some cases, PharmaCare may cover a drug only for people who have the illness or condition and have not responded to other drugs used to treat that illness or condition. For more information on PharmaCare’s drug coverage review process, see the last page of this information sheet. Information about the drug Generic name (scientific name) vedolizumab Brand name Entyvio® Manufacturer Takeda Canada Inc. Indication Entyvio is indicated for the treatment of moderately to severely active Crohn’s disease in adult patients. Has the drug been reviewed by Yes the Common Drug For more information about the CDR’s review of vedolizumab (Entyvio®), you can Review (CDR)? Search the CDR Reports. (see the note below this table.) Public input start date Friday, November 13, 2020 Public input closing date Friday, December 11, 2020 AT MIDNIGHT How is the drug taken? Entyvio is administered by subcutaneous injection (into the skin). How often is the drug taken? Entyvio is administered every two weeks, following at least two intravenous infusions (into the vein). Ministry of Health Pharmaceutical Services Division Page 1 of 4 BC PharmaCare Drug Information — vedolizumab (Entyvio®) continued… Information about the drug General drug and/or drug Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, which study information most commonly affects the small intestine, beginning of large intestine, and rectum.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125476Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management Final Risk Evaluation and Mitigation Strategy (REMS) Review Date: May 7, 2014 Reviewer(s): George Neyarapally, Pharm.D., M.P.H. Division of Risk Management (DRISK) Team Leader: Reema Mehta, Pharm.D., M.P.H. DRISK Division Director: Claudia Manzo, Pharm.D. DRISK Drug Name(s): Entyvio (vedolizumab) Therapeutic Class: Lymphocyte α4β7 integrin receptor antagonist Dosage and Route: Solution for infusion Application Type/Number: BLA 125476, BLA 125507 Applicant/Sponsor: Takeda Pharmaceuticals OSE RCM #: 2013-1641 *** This document contains proprietary and confidential information that should not be released to the public. *** 1 Reference ID: 3502774 CONTENTS 1 INTRODUCTION ....................................................................................................... 1 1.1 Product Background............................................................................................ 1 1.2 Disease Background............................................................................................ 2 1.3 Regulatory History .............................................................................................. 2 2 MATERIALS REVIEWED .......................................................................................
    [Show full text]
  • International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
    VIEWS & REVIEWS OPEN ACCESS LEVEL OF RECOMMENDATION International Consensus Guidance for Management of Myasthenia Gravis 2020 Update Pushpa Narayanaswami, MBBS, DM, Donald B. Sanders, MD, Gil Wolfe, MD, Michael Benatar, MD, Correspondence Gabriel Cea, MD, Amelia Evoli, MD, Nils Erik Gilhus, MD, Isabel Illa, MD, Nancy L. Kuntz, MD, Janice Massey, MD, Dr. Narayanaswami Arthur Melms, MD, Hiroyuki Murai, MD, Michael Nicolle, MD, Jacqueline Palace, MD, David Richman, MD, and pnarayan@ Jan Verschuuren, MD bidmc.harvard.edu Neurology® 2021;96:114-122. doi:10.1212/WNL.0000000000011124 Abstract Objective To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting “yes”) was used to approve minor changes in grammar and syntax to improve clarity. Results The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.
    [Show full text]
  • Annex I Summary of Product Characteristics
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT YERVOY 5 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 5 mg ipilimumab. One 10 ml vial contains 50 mg of ipilimumab. One 40 ml vial contains 200 mg of ipilimumab. Ipilimumab is a fully human anti-CTLA-4 monoclonal antibody (IgG1κ) produced in Chinese hamster ovary cells by recombinant DNA technology. Excipients with known effect: Each ml of concentrate contains 0.1 mmol sodium, which is 2.30 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to pale yellow liquid that may contain light (few) particulates and has a pH of 7.0 and an osmolarity of 260-300 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Melanoma YERVOY as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1). Renal cell carcinoma (RCC) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).
    [Show full text]
  • Datasheet: HCA295 Product Details
    Datasheet: HCA295 Description: HUMAN ANTI VEDOLIZUMAB Specificity: VEDOLIZUMAB Other names: Entyvio Format: Purified Product Type: Monoclonal Antibody Clone: AbD30139_hIgG1 Isotype: IgG1 Quantity: 0.1 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution ELISA Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls. Product Form Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid. Preparation Purified IgG prepared by affinity chromatography on Protein A Buffer Solution Phosphate buffered saline Preservative 0.01% Thiomersal Stabilisers Approx. Protein Antibody concentration 0.5 mg/ml Concentrations Immunogen Vedolizumab Specificity Human Anti-Vedolizumab Antibody, AbD30139_hIgG1 is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug vedolizumab. The antibody does not recognize free recombinant human α4β7 integrin or vedolizumab in complex with α4β7 integrin and can be used to measure free vedolizumab levels in serum from patients. Clone AbD30139_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Immune Checkpoint Inhibitor Therapy-Associated Encephalitis: a Case Series and Review of the Literature
    Original article | Published 23 November 2020 | doi:10.4414/smw.2020.20377 Cite this as: Swiss Med Wkly. 2020;150:w20377 Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature Stuby Johanna, Herren Thomasb, Schwegler Naumburger Guidoc, Papet Claudiad, Rudiger Alaina a Internal Medicine, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland b Cardiology, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland c Neurology, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland d Oncology/Haematology, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland Summary EEG should be performed. Therapy with intravenous corti- costeroids is recommended. Steroid unresponsiveness is BACKGROUND: Immune checkpoint inhibitors (ICIs) can rare and should lead to a review of the diagnosis. Alterna- cause a wide spectrum of immune-related adverse events, tive treatment options are IVIG, plasma exchange therapy including encephalitis. To date, no prospective ran- and rituximab. domised controlled trials examining the patient charac- teristics, treatment and outcomes of ICI-associated en- Keywords: immune checkpoint inhibitor, nivolumab, pem- cephalitis have been published. Therefore, we aimed to brolizumab, ipilimumab, encephalitis review case reports and to provide recommendations for the management of ICI-associated encephalitis. Introduction METHODS: A literature search using Google Scholar and Immune checkpoint inhibitors (ICIs) re-establish the anti- PubMed was performed in December 2019. Published tumour activity of T-lymphocytes by blocking immune in- case reports and case series of ICI-associated encephali- hibitory receptors such as programmed cell death protein 1 tis were reviewed, and a case series from the Limmattal (PD-1, e.g., nivolumab, pembrolizumab and lambrolizum- Hospital in Schlieren, Switzerland was added.
    [Show full text]
  • Entyvio (Vedolizumab) C6773-A R
    Prior Authorization Criteria Entyvio (vedolizumab) Policy Number: C6773-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DATE 09/2014 03/28/2019 03/2/2020 J CODE TYPE OF CRITERIA LAST P&T APPROVAL J3380 Inj, vedolizumab, 1 mg RxPA Q2 2019 PRODUCTS AFFECTED: Entyvio (vedolizumab) DRUG CLASS: Integrin Receptor Antagonists ROUTE OF ADMINISTRATION: Intravenous PLACE OF SERVICE: Specialty Pharmacy or Buy and Bill AVAILABLE DOSAGE FORMS: Entyvio SOLR 300MG (300MG Intravenous Solution) FDA-APPROVED USES: Crohn Disease: Treatment of moderately to severely active Crohn disease in patients who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor-alpha (TNF-alpha) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Ulcerative Colitis: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response with, lost response to, were intolerant to a tumor necrosis factor alpha (TNF-alpha) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: Documented diagnosis of moderately to severely active ulcerative colitis (UC), OR moderately to severely active Crohn disease (CD) REQUIRED MEDICAL INFORMATION: A. CROHNS DISEASE AND ULCERATIVE COLITIS: 1. A negative tuberculin skin test (TST), or CDC-recommended equivalent, for latent tuberculosis within the last 12 months, OR No evidence of active, severe infections, significant localized infections, or sepsis as documented by a recent evaluation and screening (within the past 30 days) 2.
    [Show full text]
  • The Antitumor Immunity of Ipilimumab: (T-Cell) Memories to Last a Lifetime?
    Published OnlineFirst February 15, 2012; DOI: 10.1158/1078-0432.CCR-12-0409 Clinical Cancer CCR Translations Research Commentary on Prieto et al., p. 2039 The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime? Michael A. Postow1,3, Margaret K. Callahan1,3, and Jedd D. Wolchok1,2,3,4 Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients’ unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity. Clin Cancer Res; 18(7); 1821–3. Ó2012 AACR. In this issue of Clinical Cancer Research, Prieto and col- Prieto and colleagues have assembled findings from the leagues (1) report long-term follow-up data for 177 patients largest reported long-term clinical experience with ipilimu- treated with ipilimumab in some of the earliest trials in its mab. They provide updated data from 3 previously development. Their results underscore the remarkable, published studies that examined ipilimumab with gp100 durable benefits a subset of patients with melanoma achieve vaccination [protocol 1 (6)]; ipilimumab with concomitant from ipilimumab, hint at the promise of combining ipili- IL-2 [protocol 2 (7)]; and ipilimumab via a strategy of mumab with interleukin 2 (IL-2), and raise the provocative intrapatient dose escalation (Æ gp100) until occurrence of question of whether, in some patients, metastatic melano- response or intolerable side effects [protocol 3 (8)]. The ma can be cured. authors evaluate a total of 177 patients treated with ipili- Ipilimumab (Yervoy; Bristol-Myers Squibb) is a fully mumab, with a median follow-up of 92, 84, and 71 months, human monoclonal antibody that blocks cytotoxic respectively.
    [Show full text]
  • Ipilimumab for the Treatment of Metastatic Melanoma Hansoo Kim*, Samantha Comey, Karl Hausler and Greg Cook
    Kim et al. Journal of Pharmaceutical Policy and Practice (2018) 11:4 DOI 10.1186/s40545-018-0131-4 RESEARCH Open Access A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma Hansoo Kim*, Samantha Comey, Karl Hausler and Greg Cook Abstract Background: Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the sponsor entering a ‘managed entry scheme’ to assess the 2-year overall survival rate in metastatic melanoma patients who received ipilimumab in the first year of Pharmaceutical Benefits Scheme listing. Methods: All unresectable stage IIIc / IV metastatic melanoma patients treated with at least one dose of ipilimumab therapy in Australia from the PBS listing date to a time point 12 months later (i.e. from 1-Aug-2013 to 31-Jul-2014) were invited to participate. Overall survival at 2 years post treatment initiation was measured, with Cox regression analysis used to examine the relationship between survival and patient baseline characteristics. Results: The evaluable population (910 patients) was on average 63.3 years old, male (70.1%) and treated in a public hospital (64.4%) in an urban area (76.5%). The majority of patients were treatment naïve (63.3%), did not have brain metastases (71.1%), and were classified as ECOG performance status 0 or 1 (90.4%). The 2 year overall survival rate was conservatively calculated to be at least 23.9% and potentially as high as 34.2%. A significant difference in overall survival at 2 years was demonstrated across the categories of ECOG performance status (p < 0.0001), M-status (p = 0.0005) and treatment status (p = 0.0114).
    [Show full text]